2 results
Not approvedWill not start
Primary ObjectiveTo determine whether GWP42003-P affects the pharmacokinetic (PK) profile of stiripentol (STP) or valproate (VPA).Secondary Objective(s)To assess the safety and tolerability of GWP42003-P in the presence of STP or VPA.
Approved WMOPending
To find a suitable treatment option for the 25% of HS patients who are therapy-resistant. Additionally, we expect a faster healing time of the wounds, meaning that even if patients respond to current treatment, HBOT may improve their quality of life…